Insys Therapeutics Inc. (fka INSYQ)

[terry hallinan]

5 of the Most Hated Biotech Stocks on the Market: Are They Buys?

https://www.fool.com/investing/2017/09/01/5-of-the-most-hated-biotech-stocks-on-the-market-a.aspx

-

Insys Therapeutics

Nearly 41% of Insys Therapeutics' stock float is sold short. Sales for Insys' opioid painkiller Subsys have plunged in the midst of the national opioid epidemic. Insys stock has also dropped, making some short-sellers plenty of money along the way.

I wouldn't count on a dark cloud hovering over Insys for much longer, though. The company recently launched Syndros, its cannabinoid treatment for anorexia associated with weight loss in AIDS patients and nausea and vomiting associated with chemotherapy in cancer patients.

There are also signs that the worst days for Subsys could be coming to a close. I recently picked Insys as one of three marijuana stocks that could be big winners by the end of the year, and still think the biotech could rebound significantly in the coming months.

-

Kindly note the Motley Fool author's wording: "still think."

That signals the Fool author like your wandering vagrant haven't been exacly Nostradamus's in predicting the future price for INSY.

I am personally rather favorably inclined toward buying more of this falling knife but maybe only if it takes a stand against the loudmouth politicos in court as well as in print.

A further political problem is that the adorable scientific ladies and gentlemen of the FDA only consented to lower INSY's synthetic cannabinoids to dangerous Class II addictive substances though the pure synthetic joy juice of Cannabis [THC] has been an approved drug for more than two decades because it is not addictive.

That isn't isn't scientific or rational or literate. It is, if you will pardon the ugly expression: political.

Best, Terry